How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?

Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi: 10.2217/fon.13.60)

Full text not currently available from Enlighten.

Abstract

A number of Phase II/III clinical trials have now been reported assessing the role of cetuximab use in combination with chemotherapy for the first-line treatment of metastatic colorectal cancer. Here we review the current position of cetuximab in this context from two important perspectives. First, we address whether clinicians should prioritize its use with oxaliplatin- or irinotecan-based chemotherapy doublets. Second, we review the trial evidence for the use of cetuximab in patients suffering from colorectal cancer with wild-type and mutant Ras.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Lindsay, Dr Colin and Graham, Dr Janet and Roxburgh, Dr Patricia
Authors: Lindsay, C. R., Roxburgh, P., and Graham, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Future Oncology
Publisher:Future Medicine Ltd.
ISSN:1479-6694
ISSN (Online):1744-8301

University Staff: Request a correction | Enlighten Editors: Update this record